Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H20N2.2C8H11NO5S |
Molecular Weight | 706.827 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC(=O)N1[C@@H](C(O)=O)C(C)(C)S2(=O)=O.[H][C@@]34CC(=O)N3[C@@H](C(O)=O)C(C)(C)S4(=O)=O.C(CNCC5=CC=CC=C5)NCC6=CC=CC=C6
InChI
InChIKey=YSEPFTSCLHUBNH-HFKSPEPWSA-N
InChI=1S/C16H20N2.2C8H11NO5S/c1-3-7-15(8-4-1)13-17-11-12-18-14-16-9-5-2-6-10-16;2*1-8(2)6(7(11)12)9-4(10)3-5(9)15(8,13)14/h1-10,17-18H,11-14H2;2*5-6H,3H2,1-2H3,(H,11,12)/t;2*5-,6+/m.11/s1
DescriptionCurator's Comment: description was created based on several sources, including
https://en.wikipedia.org/wiki/Sulbactam
http://www.drugbank.ca/drugs/DB09324
Curator's Comment: description was created based on several sources, including
https://en.wikipedia.org/wiki/Sulbactam
http://www.drugbank.ca/drugs/DB09324
Sulbactam is a β-lactamase inhibitor given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys the antibiotics. Sulbactam in combination with semisynthetic antibiotic ampicillin sodium is indicated for the treatment of infections due to susceptible strains of the designated microorganisms: Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli etc; Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. Pneumoniae) tec; Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, and Bacteroides spp. (including B. fragilis).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P62593 Gene ID: 10076131|||10076142|||13876868|||13877052|||13903673|||13905334|||13905363|||13906404|||13906709|||13906924|||13909533|||13909568|||14612524|||17824300|||17824435|||18157686|||20466965|||20466993|||20467118|||20468340|||20471961|||20491414|||20491639|||20492529|||20492626|||20493584|||2716540|||3244915|||3722457|||4924718|||5961992|||6276043|||8319064|||8319163|||9537966|||9538101|||9846067 Gene Symbol: bla|||blaT-3|||blaT-4|||blaT-5|||blaT-6 Target Organism: Escherichia coli |
0.062 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | UNASYN Approved UseSulbactam Launch Date1988 |
|||
Curative | UNASYN Approved UseSulbactam Launch Date1988 |
|||
Curative | UNASYN Approved UseSulbactam Launch Date1988 |
|||
Curative | UNASYN Approved UseUNASYN is an injectable antibacterial combination consisting of the semisynthetic antibiotic ampicillin sodium and the beta-lactamase inhibitor sulbactam sodium for intravenous and intramuscular administration Launch Date1988 |
|||
Curative | UNASYN Approved UseSulbactam Launch Date1988 |
|||
Curative | UNASYN Approved UseSulbactam Launch Date1988 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15.36 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
0.5 g single, intramuscular dose: 0.5 g route of administration: Intramuscular experiment type: SINGLE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
40.33 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
0.5 g single, intramuscular dose: 0.5 g route of administration: Intramuscular experiment type: SINGLE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
40.71 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
0.5 g 1 times / day steady-state, intravenous dose: 0.5 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
83.79 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
1 g 1 times / day steady-state, intravenous dose: 1 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.26 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
0.5 g single, intramuscular dose: 0.5 g route of administration: Intramuscular experiment type: SINGLE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
0.5 g 1 times / day steady-state, intravenous dose: 0.5 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
1 g 1 times / day steady-state, intravenous dose: 1 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1 h |
SULBACTAM serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
62% |
SULBACTAM serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
4 g 3 times / day multiple, intravenous Highest studied dose Dose: 4 g, 3 times / day Route: intravenous Route: multiple Dose: 4 g, 3 times / day Co-administed with:: ampicillin, i.v(8 g, t.i.d) Sources: Page: p.5meropenem, i.v(2g, t.i.d) polymyxin B, i.v(1.43 mg/kg, b.i.d) |
unhealthy n = 13 Health Status: unhealthy Condition: Ventilator-associated pneumonia, caused by colistin-resistant A. baumannii infection Population Size: 13 Sources: Page: p.5 |
|
2 g 2 times / day multiple, intravenous Recommended Dose: 2 g, 2 times / day Route: intravenous Route: multiple Dose: 2 g, 2 times / day Co-administed with:: cefoperazone, i.v Sources: |
unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
In vitro effect of ampicillin/sulbactam on Acinetobacter species. | 2001 |
|
Antibiotic susceptibility, serum response and surface properties of Klebsiella species. | 2001 |
|
Effect of granulocyte-macrophage colony-stimulating factor on treatment of acute osteomyelitis. An experimental investigation in rats. | 2001 |
|
Transferable antibiotic resistance in multiresistant nosocomial Acinetobacter baumannii strains from seven clinics in the Slovak and Czech Republics. | 2001 Apr |
|
[Fundamental and clinical studies on beta-lactamase inhibitors]. | 2001 Apr |
|
[New aspects of antibiotic resistance and possibilities of its prevention]. | 2001 Aug |
|
Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms. | 2001 Aug |
|
A randomized, double-blind comparison of ampicillin/sulbactam and ceftriaxone in the prevention of surgical-site infections after neurosurgery. | 2001 Aug |
|
Hepatotoxic reactions induced by beta-lactamase inhibitors. | 2001 Dec 17 |
|
Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. | 2001 Feb |
|
Inhibition of the SHV-1 beta-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam. | 2001 Feb 13 |
|
Penicillins and beta-lactamase inhibitor combinations. | 2001 Jun 15 |
|
[Clinical analysis of neutropenic fever associated with hematological disorders]. | 2001 Mar |
|
An anaphylactic reaction possibly associated with an intraoperative coronary artery spasm during general anesthesia. | 2001 May |
|
Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. | 2001 Nov 1 |
|
The penetration of cefoperazone and sulbactam into the lumbar intervertebral discs. | 2001 Oct |
|
Role of sultamicillin and ampicillin/sulbactam in the treatment of upper and lower bacterial respiratory tract infections. | 2001 Sep |
|
Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis. | 2002 Apr |
|
Bacteriology and antimicrobial susceptibility of gram-positive cocci isolated from pus specimens of orofacial odontogenic infections. | 2002 Apr |
|
[Acinetobacter, a nosocomial pathogen. Contribution of experimental models]. | 2002 Apr 13 |
|
Pharmacokinetics of an ampicillin/sulbactam (2:1) combination in rabbits. | 2002 Aug |
|
Application of micellar electrokinetic chromatography to the determination of sultamicillin in oral pharmaceutical preparations. | 2002 Dec 6 |
|
[Analysis of prophylactic antibiotics for cesarean section]. | 2002 Jan |
|
Prevalence of and resistance to anti-microbial drugs in selected microbial species isolated from bulk milk samples. | 2002 Jun |
|
Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients. | 2002 Jun |
|
The role of cefoperazone-sulbactam for treatment of severe melioidosis. | 2002 Mar 1 |
|
Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. | 2003 Jan |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: UNASYN should be administered by slow intravenous injection over at least 10–15 minutes or can also be delivered in greater dilutions with 50–100 mL of a compatible diluent as an intravenous infusion over 15–30 minutes.
The recommended adult dosage of UNASYN is 1.5 g (1 g ampicillin as the sodium salt plus 0.5 g sulbactam as the sodium salt) to 3 g (2 g ampicillin as the sodium salt plus 1 g sulbactam as the sodium salt) every six hours
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C471
Created by
admin on Fri Dec 15 16:22:28 GMT 2023 , Edited by admin on Fri Dec 15 16:22:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11954361
Created by
admin on Fri Dec 15 16:22:28 GMT 2023 , Edited by admin on Fri Dec 15 16:22:28 GMT 2023
|
PRIMARY | |||
|
DBSALT002843
Created by
admin on Fri Dec 15 16:22:28 GMT 2023 , Edited by admin on Fri Dec 15 16:22:28 GMT 2023
|
PRIMARY | |||
|
83031-43-0
Created by
admin on Fri Dec 15 16:22:28 GMT 2023 , Edited by admin on Fri Dec 15 16:22:28 GMT 2023
|
PRIMARY | |||
|
49MU89FVBV
Created by
admin on Fri Dec 15 16:22:28 GMT 2023 , Edited by admin on Fri Dec 15 16:22:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL403
Created by
admin on Fri Dec 15 16:22:28 GMT 2023 , Edited by admin on Fri Dec 15 16:22:28 GMT 2023
|
PRIMARY | |||
|
C90848
Created by
admin on Fri Dec 15 16:22:28 GMT 2023 , Edited by admin on Fri Dec 15 16:22:28 GMT 2023
|
PRIMARY | |||
|
DTXSID701003088
Created by
admin on Fri Dec 15 16:22:28 GMT 2023 , Edited by admin on Fri Dec 15 16:22:28 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD